Niemi M - Search Results

1

Ramsey LB, Gong L, Lee SB, Wagner JB, Zhou X, Sangkuhl K, Adams SM, Straka RJ, Empey PE, Boone EC, Klein TE, Niemi M, Gaedigk A. Ramsey LB, et al. Among authors: niemi m. Clin Pharmacol Ther. 2023 Apr;113(4):782-793. doi: 10.1002/cpt.2705. Epub 2022 Jul 27. Clin Pharmacol Ther. 2023. PMID: 35797228 Free PMC article. Review.

2

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.

Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Niemi M, et al. Clin Pharmacol Ther. 2003 Oct;74(4):380-7. doi: 10.1016/S0009-9236(03)00228-5. Clin Pharmacol Ther. 2003. PMID: 14534525 Clinical Trial.

3

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ. Niemi M, et al. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018. Clin Pharmacol Ther. 2005. PMID: 15961978

4

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Kajosaari LI, et al. Among authors: niemi m. Clin Pharmacol Ther. 2005 Oct;78(4):388-99. doi: 10.1016/j.clpt.2005.07.005. Clin Pharmacol Ther. 2005. PMID: 16198658 Clinical Trial.

5

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT. Igel M, et al. Among authors: niemi m. Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11. Clin Pharmacol Ther. 2006. PMID: 16678544 Clinical Trial.

6

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.

Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Pasanen MK, et al. Among authors: niemi m. Eur J Clin Pharmacol. 2006 Jun;62(6):409-15. doi: 10.1007/s00228-006-0123-1. Epub 2006 Apr 21. Eur J Clin Pharmacol. 2006. PMID: 16758257

7

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Niemi M, Pasanen MK, Neuvonen PJ. Niemi M, et al. Clin Pharmacol Ther. 2006 Oct;80(4):356-66. doi: 10.1016/j.clpt.2006.06.010. Clin Pharmacol Ther. 2006. PMID: 17015053 Clinical Trial.

8

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Neuvonen PJ, Niemi M, Backman JT. Neuvonen PJ, et al. Among authors: niemi m. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. doi: 10.1016/j.clpt.2006.09.003. Clin Pharmacol Ther. 2006. PMID: 17178259 Review.

9

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.

Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Pasanen MK, et al. Among authors: niemi m. Clin Pharmacol Ther. 2007 Dec;82(6):726-33. doi: 10.1038/sj.clpt.6100220. Epub 2007 May 2. Clin Pharmacol Ther. 2007. PMID: 17473846

10

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Among authors: niemi m. Br J Clin Pharmacol. 2008 Jan;65(1):78-86. doi: 10.1111/j.1365-2125.2007.02986.x. Epub 2007 Jul 17. Br J Clin Pharmacol. 2008. PMID: 17635496 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

546 results

Search Page